Tumor-stroma crosstalk: Targeting stroma in breast cancer

Current Opinion in Oncology

Volumn 26, Issue 6, 2014, Pages 551-555

  Criscitiello, Carmen ^a   Esposito, Angela ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Microenvironment; Tumor stroma

Indexed keywords

ANGIOGENESIS; BREAST METASTASIS; CANCER GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; ENDOTHELIUM CELL; ENERGY METABOLISM; EXTRACELLULAR MATRIX; FIBROBLAST; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MACROPHAGE; MEDIATOR RELEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; FEMALE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84927619757     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000122     Document Type: Review

References (32)

1. Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009; 11:R7.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-322.
3. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335-348.
4. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006; 12:296-300.
5. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007; 117:3155-3163.
6. Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia 2010; 15:301-318.
7. Bauer M, Su G, Casper C, et al. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010; 29:1732-1740.
8. Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009; 4:e7965.
9. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012; 31:195-208.
10. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501:346-354.
11. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67.
12. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214:357-367.
13. Triulzi T, Casalini P, Sandri M, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 2013; 8:e56761.
14. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2:E7.
15. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med 2008; 14:518-527.
16. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
17. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989; 320:1211-1212.
18. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxiaassociated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012; 21:66-81.
19. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011; 1:482-497.
20. Paunescu V, Bojin FM, Tatu CA, et al. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med 2011; 15:635-646.
21. Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40:650-655.
22. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 2012; 12:252-264.
23. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
24. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
25. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
26. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011; 108:7142-7147.
27. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122:787-795.
28. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11:519-531.
29. Curigliano G, Criscitiello C. Successes and limitations of targeted cancer therapy in breast cancer. Prog Tumor Res 2014; 41:15-35.
30. Morandi A, Martin LA, Gao Q, et al.GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res 2013; 73:3783-3795.
31. Martinez-Outschoorn UE, Goldberg A, Lin Z, et al. Antiestrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011; 12:924-938.
32. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68-74.